Key Highlights
- Loss per share was USD 1.74 against an estimate of a USD 0.82 loss.
- Collaboration Revenue was USD 2.22 million against an estimate of USD 2.58 million.
- Net loss was USD 28.12 million, against USD 17.88 million a year earlier.
- Cash and short-term investments were USD 901.0 million at September 30.
ADARx Pharmaceuticals (NASDAQ:ADRX) reported a third quarter 2026 loss per share of USD 1.74, against an estimate of a USD 0.82 loss and a USD 1.85 loss in the third quarter of 2025. Collaboration revenue was USD 2.22 million, against an estimate of USD 2.58 million.
Net loss was USD 28.12 million, compared with USD 17.88 million. The loss from operations was USD 32.18 million, compared with USD 23.01 million.
Operating Expenses
Research and development expenses were USD 26.71 million, compared with USD 19.42 million. General and administrative expenses were USD 7.68 million, compared with USD 5.15 million. Total operating expenses were USD 34.39 million, compared with USD 24.56 million. Interest income was USD 3.48 million.
For the nine months ended September 30, 2026, net loss was USD 76.54 million, compared with USD 51.53 million, and the loss per share was USD 6.46, compared with USD 5.35. Total operating expenses were USD 94.23 million, compared with USD 63.78 million, and the loss from operations was USD 89.12 million, compared with USD 62.02 million.
Research and development expenses for the nine months were USD 75.03 million, compared with USD 49.38 million, and general and administrative expenses were USD 19.20 million, compared with USD 14.40 million. The weighted-average shares outstanding for the quarter were 16,127,078.
Cash and Initial Public Offering
As of September 30, 2026, the company had cash, cash equivalents and short-term investments of USD 901.0 million, comprising cash and cash equivalents of USD 570.61 million, compared with USD 66.52 million at the prior Balance Sheet date, and short-term investments of USD 330.40 million, compared with USD 413.48 million.
The company believes its existing cash, cash equivalents and short-term investments, together with net proceeds received in October 2026 from the full exercise of the underwriters' option to purchase additional shares in its IPO, are sufficient to fund its operations. The filing states that the company received net proceeds of approximately USD 62.3 million from that exercise, after deducting Underwriting discounts and commissions of approximately USD 4.6 million.
Pipeline
The filing states that the company's Phase 1 clinical trial evaluated the safety, tolerability, pharmacokinetic activity and pharmacodynamic activity of agazisiran, and that it is conducting three Phase 2 Clinical Trials evaluating the efficacy and safety of agazisiran in patients with complement-mediated diseases, including renal diseases such as IgA nephropathy, complement 3 glomerulopathy and immune complex membranoproliferative glomerulonephritis. The filing also names onvuzosiran and ADX-626 as programs, along with two extrahepatic-targeted programs, ADX-077 and ADX-199.
The balance sheet reports total liabilities of USD 354.66 million, an accumulated Deficit of USD 297.24 million and total stockholders' Equity of USD 574.40 million. For the nine months, net cash provided by investing activities was USD 78.61 million and net cash provided by financing activities was USD 502.10 million.
ADARx Pharmaceuticals Q3 2026 Earnings: Key Takeaways
ADARx Pharmaceuticals reported a third quarter 2026 loss per share of USD 1.74 and a net loss of USD 28.12 million. Cash, cash equivalents and short-term investments were USD 901.0 million.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...